View in EDS PDF Full Text

Tratamiento de epistaxis en pacientes con COVID-19.

Saved in:
Bibliographic Details
Title: Tratamiento de epistaxis en pacientes con COVID-19.
Alternate Title: Management of epistaxis in COVID-19 patients.
Authors: Gasós-Lafuente, Ana María1 anagasos01@gmail.com, Lavilla-Martín de Valmaseda, María José1, Navarro-Mediano, Andrés2, Martínez-Ruiz Coello, Mar2, Plaza-Mayor, Guillermo2, García-Purriños, Francisco3, Mateos-Serrano, Blanca4, Campos-González, Alfonso5, Miguel Villacampa-Aubá, José5, Estévez-Alonso, Santiago6, Rey Tomás-Biosca, Francisco Javier Del7, Lois-Ortega, Yolanda7, Úbeda Fernández, Esther8, Martin-Villares, Cristina9, Morales-Angulo, Carmelo10
Source: Anales de Otorrinolaringología Mexicana. Jan-Mar2021, Vol. 66 Issue 1, p43-51. 9p.
Abstract (English): BACKGROUND: The use of anticoagulants and high-flow oxygen therapy are therapies that may predispose to epistaxis. Both factors often coexist in patients affected by SARSCoV-2, which caused the recent global pandemic of COVID-19. OBJECTIVE: To investigate the clinical-epidemiological characteristics of patients with COVID-19 who develop epistaxis, as well as its triggers and management, among others. MATERIALS AND METHODS: A multicenter, retrospective, descriptive study in COVID-19 patients with a positive PCR test who presented epistaxis throughout the disease. Study was done from January 31st May 19th, 2020. Demographic data were collected on previous comorbidities, treatments, complications related to COVID-19, triggers, severity of epistaxis, treatment indicated and evolution, among others. RESULTS: A total of 18 patients between the ages of 54 and 88 were included, and 72% were male. They were attended in 9 different hospitals throughout Spain, presenting between 1 to 3 cases each. In 83.3% of the patients epistaxis had some specific trigger, being multiple in 16.6% of them. However, nasopharyngeal smear taken for PCR was not the cause in any case. The most frequent type of treatment was an anterior nasal packing.\\\CONCLUSIONS: Although patients with COVID-19 constitute a special risk group for epistaxis given their associated comorbidities, severe epistaxis is rare in this group of patients. The management of these patients is also complex due to the working conditions when assisting these patients and should always keep healthcare workers safe. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): ANTECEDENTES: La administración de anticoagulantes y la oxigenoterapia de alto flujo son factores que predisponen a mayor riesgo de epistaxis. Ambos factores concurren muchas veces en pacientes infectados con el virus SARS-CoV-2. OBJETIVO: Investigar las características clínico-epidemiológicas de pacientes con COVID-19 y epistaxis, así como las causas y tratamiento. MATERIALES Y MÉTODOS: Estudio descriptivo, retrospectivo, multicéntrico, efectuado del 31 de enero al 19 de mayo de 2020 en pacientes con COVID-19 con PCR positiva que tuvieron epistaxis a lo largo de la enfermedad. Se recogieron datos demográficos, complicaciones relacionadas con el COVID-19, desencadenantes de la epistaxis, gravedad, tratamiento prescrito y evolución, entre otros. RESULTADOS: Se incluyeron 18 pacientes, de 54 a 88 años de edad, asistidos en 9 hospitales de toda España, con uno a tres casos cada uno de ellos. En el 83.3% de los pacientes la epistaxis tuvo algún desencadenante concreto, fue múltiple en el 16.6% de ellos, ninguno fue secundario al frotis nasofaríngeo para la realización de PCR. El tratamiento más indicado fue el taponamiento nasal anterior. CONCLUSIONES: Los pacientes con COVID-19 constituyen un grupo de especial riesgo de epistaxis debido a sus comorbilidades; los sangrados graves son infrecuentes. El manejo es complejo por las condiciones de trabajo al momento de asistir a estos pacientes con el fin de evitar el contagio de los profesionales en todo momento. [ABSTRACT FROM AUTHOR]
Copyright of Anales de Otorrinolaringología Mexicana is the property of Sociedad Mexicana de Otorrinolaringologia y Cirugia de Cabeza y Cuello and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 149932962
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Tratamiento de epistaxis en pacientes con COVID-19.
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: Management of epistaxis in COVID-19 patients.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Gasós-Lafuente%2C+Ana+María%22">Gasós-Lafuente, Ana María</searchLink><relatesTo>1</relatesTo><i> anagasos01@gmail.com</i><br /><searchLink fieldCode="AR" term="%22Lavilla-Martín+de+Valmaseda%2C+María+José%22">Lavilla-Martín de Valmaseda, María José</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Navarro-Mediano%2C+Andrés%22">Navarro-Mediano, Andrés</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Martínez-Ruiz+Coello%2C+Mar%22">Martínez-Ruiz Coello, Mar</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Plaza-Mayor%2C+Guillermo%22">Plaza-Mayor, Guillermo</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22García-Purriños%2C+Francisco%22">García-Purriños, Francisco</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Mateos-Serrano%2C+Blanca%22">Mateos-Serrano, Blanca</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Campos-González%2C+Alfonso%22">Campos-González, Alfonso</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Miguel+Villacampa-Aubá%2C+José%22">Miguel Villacampa-Aubá, José</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Estévez-Alonso%2C+Santiago%22">Estévez-Alonso, Santiago</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Rey+Tomás-Biosca%2C+Francisco+Javier+Del%22">Rey Tomás-Biosca, Francisco Javier Del</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Lois-Ortega%2C+Yolanda%22">Lois-Ortega, Yolanda</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Úbeda+Fernández%2C+Esther%22">Úbeda Fernández, Esther</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Martin-Villares%2C+Cristina%22">Martin-Villares, Cristina</searchLink><relatesTo>9</relatesTo><br /><searchLink fieldCode="AR" term="%22Morales-Angulo%2C+Carmelo%22">Morales-Angulo, Carmelo</searchLink><relatesTo>10</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Anales+de+Otorrinolaringología+Mexicana%22">Anales de Otorrinolaringología Mexicana</searchLink>. Jan-Mar2021, Vol. 66 Issue 1, p43-51. 9p.
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: BACKGROUND: The use of anticoagulants and high-flow oxygen therapy are therapies that may predispose to epistaxis. Both factors often coexist in patients affected by SARSCoV-2, which caused the recent global pandemic of COVID-19. OBJECTIVE: To investigate the clinical-epidemiological characteristics of patients with COVID-19 who develop epistaxis, as well as its triggers and management, among others. MATERIALS AND METHODS: A multicenter, retrospective, descriptive study in COVID-19 patients with a positive PCR test who presented epistaxis throughout the disease. Study was done from January 31st May 19th, 2020. Demographic data were collected on previous comorbidities, treatments, complications related to COVID-19, triggers, severity of epistaxis, treatment indicated and evolution, among others. RESULTS: A total of 18 patients between the ages of 54 and 88 were included, and 72% were male. They were attended in 9 different hospitals throughout Spain, presenting between 1 to 3 cases each. In 83.3% of the patients epistaxis had some specific trigger, being multiple in 16.6% of them. However, nasopharyngeal smear taken for PCR was not the cause in any case. The most frequent type of treatment was an anterior nasal packing.\\\CONCLUSIONS: Although patients with COVID-19 constitute a special risk group for epistaxis given their associated comorbidities, severe epistaxis is rare in this group of patients. The management of these patients is also complex due to the working conditions when assisting these patients and should always keep healthcare workers safe. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: ANTECEDENTES: La administración de anticoagulantes y la oxigenoterapia de alto flujo son factores que predisponen a mayor riesgo de epistaxis. Ambos factores concurren muchas veces en pacientes infectados con el virus SARS-CoV-2. OBJETIVO: Investigar las características clínico-epidemiológicas de pacientes con COVID-19 y epistaxis, así como las causas y tratamiento. MATERIALES Y MÉTODOS: Estudio descriptivo, retrospectivo, multicéntrico, efectuado del 31 de enero al 19 de mayo de 2020 en pacientes con COVID-19 con PCR positiva que tuvieron epistaxis a lo largo de la enfermedad. Se recogieron datos demográficos, complicaciones relacionadas con el COVID-19, desencadenantes de la epistaxis, gravedad, tratamiento prescrito y evolución, entre otros. RESULTADOS: Se incluyeron 18 pacientes, de 54 a 88 años de edad, asistidos en 9 hospitales de toda España, con uno a tres casos cada uno de ellos. En el 83.3% de los pacientes la epistaxis tuvo algún desencadenante concreto, fue múltiple en el 16.6% de ellos, ninguno fue secundario al frotis nasofaríngeo para la realización de PCR. El tratamiento más indicado fue el taponamiento nasal anterior. CONCLUSIONES: Los pacientes con COVID-19 constituyen un grupo de especial riesgo de epistaxis debido a sus comorbilidades; los sangrados graves son infrecuentes. El manejo es complejo por las condiciones de trabajo al momento de asistir a estos pacientes con el fin de evitar el contagio de los profesionales en todo momento. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Anales de Otorrinolaringología Mexicana is the property of Sociedad Mexicana de Otorrinolaringologia y Cirugia de Cabeza y Cuello and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=149932962
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.24245/aorl.v66i1.4845
    Languages:
      – Code: spa
        Text: Spanish
    PhysicalDescription:
      Pagination:
        PageCount: 9
        StartPage: 43
    Titles:
      – TitleFull: Tratamiento de epistaxis en pacientes con COVID-19.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gasós-Lafuente, Ana María
      – PersonEntity:
          Name:
            NameFull: Lavilla-Martín de Valmaseda, María José
      – PersonEntity:
          Name:
            NameFull: Navarro-Mediano, Andrés
      – PersonEntity:
          Name:
            NameFull: Martínez-Ruiz Coello, Mar
      – PersonEntity:
          Name:
            NameFull: Plaza-Mayor, Guillermo
      – PersonEntity:
          Name:
            NameFull: García-Purriños, Francisco
      – PersonEntity:
          Name:
            NameFull: Mateos-Serrano, Blanca
      – PersonEntity:
          Name:
            NameFull: Campos-González, Alfonso
      – PersonEntity:
          Name:
            NameFull: Miguel Villacampa-Aubá, José
      – PersonEntity:
          Name:
            NameFull: Estévez-Alonso, Santiago
      – PersonEntity:
          Name:
            NameFull: Rey Tomás-Biosca, Francisco Javier Del
      – PersonEntity:
          Name:
            NameFull: Lois-Ortega, Yolanda
      – PersonEntity:
          Name:
            NameFull: Úbeda Fernández, Esther
      – PersonEntity:
          Name:
            NameFull: Martin-Villares, Cristina
      – PersonEntity:
          Name:
            NameFull: Morales-Angulo, Carmelo
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: Jan-Mar2021
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 16655672
          Numbering:
            – Type: volume
              Value: 66
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Anales de Otorrinolaringología Mexicana
              Type: main
ResultId 1